Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

NLM Logo

ogalvibart, crexavibart drug combination MeSH Supplementary Concept Data 2025


MeSH Supplementary
ogalvibart, crexavibart drug combination
Unique ID
C000712627
RDF Unique Identifier
http://id.nlm.nih.gov/mesh/C000712627
Entry Term(s)
BMS-986413 and BMS-986414
BMS-986413 and BMS-986414 drug combination
BMS-986413, BMS-986414 drug combination
C-144-LS and C-135-LS
C-144-LS and C-135-LS drug combination
C-144-LS, C-135-LS
C-144-LS, C-135-LS drug combination
C144-LS and C-135-LS drug combination
C144-LS and C135-LS drug combination
C144-LS, C-135-LS drug combination
C144-LS, C135-LS drug combination
IM-051
IM051
ogalvibart and crexavibart
ogalvibart and crexavibart drug combination
Registry Numbers
0
Heading Mapped to
Drug Combinations
*Antibodies, Neutralizing
*Antibodies, Monoclonal, Humanized
Frequency
0
Note
combination of two neutralizing anti-SARS-CoV-2 mAbs targeting epitopes on the receptor protein binding domain (RBD) of the SARS-CoV-2 spike protein
Date of Entry
2021/01/25
Revision Date
2022/05/27
ogalvibart, crexavibart drug combination Preferred
C-144-LS and C-135-LS Narrower
IM-051 Narrower
BMS-986413 and BMS-986414 Narrower
page delivered in 0.005s